- Home
- KB vs BIIB Comparison
KB vs BIIB Comparison
Compare KB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KB
- BIIB
- Stock Information
- Founded
- KB 2008
- BIIB 1978
- Country
- KB South Korea
- BIIB United States
- Employees
- KB N/A
- BIIB N/A
- Industry
- KB Commercial Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- KB Finance
- BIIB Health Care
- Exchange
- KB Nasdaq
- BIIB Nasdaq
- Market Cap
- KB 22.1B
- BIIB 25.1B
- IPO Year
- KB N/A
- BIIB 1991
- Fundamental
- Price
- KB $58.11
- BIIB $149.78
- Analyst Decision
- KB
- BIIB Buy
- Analyst Count
- KB 0
- BIIB 26
- Target Price
- KB N/A
- BIIB $248.00
- AVG Volume (30 Days)
- KB 281.3K
- BIIB 1.6M
- Earning Date
- KB 10-24-2024
- BIIB 02-11-2025
- Dividend Yield
- KB 3.83%
- BIIB N/A
- EPS Growth
- KB 5.68
- BIIB 10.05
- EPS
- KB 8.78
- BIIB 11.06
- Revenue
- KB $10,742,590,155.00
- BIIB $9,607,500,000.00
- Revenue This Year
- KB N/A
- BIIB N/A
- Revenue Next Year
- KB N/A
- BIIB N/A
- P/E Ratio
- KB $6.56
- BIIB $13.47
- Revenue Growth
- KB 6.32
- BIIB N/A
- 52 Week Low
- KB $36.57
- BIIB $145.07
- 52 Week High
- KB $72.89
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- KB 35.83
- BIIB 31.81
- Support Level
- KB $58.32
- BIIB $145.07
- Resistance Level
- KB $59.68
- BIIB $149.92
- Average True Range (ATR)
- KB 0.89
- BIIB 3.57
- MACD
- KB -0.06
- BIIB 0.18
- Stochastic Oscillator
- KB 21.11
- BIIB 22.27
About KB KB Financial Group Inc
KB Financial Group Inc is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segment includes the Banking business, Securities business, Non-life Insurance business, Credit card business, and life Insurance business. The Group generates the majority of its revenue from the Banking business.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.